Biogen Inc Aducanumab Webinar Update Transcript
Allow me to welcome, everyone, to this very important presentation by our colleagues from Biogen. This is John Dwyer, President of the Global Alzheimer's Platform Foundation. This was initially intended as a discussion of the science and clinical aspects of Biogen's drug aducanumab, and we broadened it to the public, which I think is terrific. So let me just say a word about who GAP is for those of you on this call that don't know us.
The Global Alzheimer's Platform Foundation's mission is to reduce the duration and cost and improve the quality of Alzheimer's disease clinical therapeutic studies. Not a trivial mission, to say the least. Over the last 6 years, we have combined with our network of over 80 truly leading clinical trial sites in North America to try and accelerate and improve clinical trials for a variety of different Alzheimer's therapies. We're proud to say one of those was Biogen's. And it is with that background that we have in our audience, all of our sites, I hope, their PIs and staff who have worked so hard to bring aducanumab to the place where it is and other very
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
